The Implementation of Mass Spectrometry-Based Proteomics Workflows in Clinical Routines of Acute Myeloid Leukemia: Applicability and Perspectives.
acute myeloid leukemia
bioinformatics pipeline
biomarker
clinical proteomics
diagnosis
laboratory robots
prognosis
treatment
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
17 Sep 2020
17 Sep 2020
Historique:
received:
28
08
2020
revised:
10
09
2020
accepted:
15
09
2020
entrez:
22
9
2020
pubmed:
23
9
2020
medline:
16
3
2021
Statut:
epublish
Résumé
With the current reproducibility of proteome preparation workflows along with the speed and sensitivity of the mass spectrometers, the transition of the mass spectrometry (MS)-based proteomics technology from biomarker discovery to clinical implementation is under appraisal in the biomedicine community. Therefore, this technology might be implemented soon to detect well-known biomarkers in cancers and other diseases. Acute myeloid leukemia (AML) is an aggressive heterogeneous malignancy that requires intensive treatment to cure the patient. Leukemia relapse is still a major challenge even for patients who have favorable genetic abnormalities. MS-based proteomics could be of great help to both describe the proteome changes of individual patients and identify biomarkers that might encourage specific treatments or clinical strategies. Herein, we will review the advances and availability of the MS-based proteomics strategies that could already be used in clinical proteomics. However, the heterogeneity of complex diseases as AML requires consensus to recognize AML biomarkers and to establish MS-based workflows that allow their unbiased identification and quantification. Although our literature review appears promising towards the utilization of MS-based proteomics in clinical AML in a near future, major efforts are required to validate AML biomarkers and agree on clinically approved workflows.
Identifiants
pubmed: 32957646
pii: ijms21186830
doi: 10.3390/ijms21186830
pmc: PMC7556012
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Proteome
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Kreftforeningen
ID : 100933
Références
J Biotechnol. 2017 Nov 10;261:116-125
pubmed: 28606611
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Nat Methods. 2009 May;6(5):359-62
pubmed: 19377485
Proteomics. 2005 May;5(7):1742-5
pubmed: 15761957
Curr Treat Options Oncol. 2017 Mar;18(3):17
pubmed: 28286924
Expert Rev Hematol. 2015 Jun;8(3):299-313
pubmed: 25835070
J Proteome Res. 2014 Dec 5;13(12):6176-86
pubmed: 25338131
Expert Rev Hematol. 2015 Jun;8(3):315-27
pubmed: 25901742
Haematologica. 2017 May;102(5):865-873
pubmed: 28126965
Cancer. 2009 Oct 15;115(20):4715-26
pubmed: 19642176
Int J Hematol. 2017 May;105(5):549-557
pubmed: 28357569
Haematologica. 2019 Jan;104(1):113-119
pubmed: 30076173
Leuk Res. 2009 Jun;33(6):779-87
pubmed: 19007987
Cancers (Basel). 2020 Mar 17;12(3):
pubmed: 32192169
PLoS Comput Biol. 2013 Apr;9(4):e1002963
pubmed: 23592955
Proteomics Clin Appl. 2015 Aug;9(7-8):745-54
pubmed: 25631240
Front Mol Biosci. 2018 Aug 27;5:76
pubmed: 30211169
Proteomics. 2017 Mar;17(6):
pubmed: 28176486
Nat Protoc. 2011 Feb;6(2):147-57
pubmed: 21293456
Hematol Oncol Stem Cell Ther. 2020 May 20;:
pubmed: 32473106
Signal Transduct Target Ther. 2019 Jun 19;4:20
pubmed: 31240133
Blood. 2020 Sep 24;136(13):1507-1519
pubmed: 32556243
Clin Proteomics. 2020 May 24;17:17
pubmed: 32489335
Expert Opin Ther Targets. 2018 Jul;22(7):639-653
pubmed: 29889583
Nat Protoc. 2006;1(4):1929-35
pubmed: 17487178
Cancers (Basel). 2019 Dec 31;12(1):
pubmed: 31906064
JAMA Oncol. 2017 Dec 1;3(12):1675-1682
pubmed: 28880971
Curr Protoc Cytom. 2019 Dec;91(1):e66
pubmed: 31763792
Nature. 2017 Nov 16;551(7680):384-388
pubmed: 29144447
Mol Syst Biol. 2019 Mar 1;15(3):e8793
pubmed: 30824564
Blood. 2012 Jan 5;119(1):55-63
pubmed: 22001391
Int J Nanomedicine. 2019 May 23;14:3819-3830
pubmed: 31213803
Int J Mol Sci. 2019 Jan 08;20(1):
pubmed: 30626126
Lancet Oncol. 2018 Feb;19(2):216-228
pubmed: 29339097
Haematologica. 2016 Jan;101(1):20-5
pubmed: 26721801
Nat Rev Clin Oncol. 2012 Oct;9(10):579-90
pubmed: 22949046
Proteomics. 2014 Sep;14(17-18):1971-6
pubmed: 25044641
Proteomics. 2008 Feb;8(4):731-49
pubmed: 18297651
Cells. 2019 Oct 10;8(10):
pubmed: 31658693
Leukemia. 2020 Feb;34(2):427-440
pubmed: 31611628
Blood. 2010 Jan 21;115(3):453-74
pubmed: 19880497
J Proteome Res. 2015 Dec 4;14(12):5378-87
pubmed: 26538118
Curr Med Chem. 2019;26(28):5293-5316
pubmed: 31032748
J Clin Med. 2015 Apr;4(4):665-95
pubmed: 25932335
J Clin Oncol. 2014 Oct 10;32(29):3249-56
pubmed: 25154831
Bone Marrow Transplant. 2019 Jan;54(1):6-16
pubmed: 29855562
Nat Med. 2011 Aug 28;17(9):1086-93
pubmed: 21873988
Nat Methods. 2014 Mar;11(3):319-24
pubmed: 24487582
Int J Biol Sci. 2019 Jan 6;15(1):1-11
pubmed: 30662342
Cells. 2020 May 07;9(5):
pubmed: 32392896
Cancer Manag Res. 2019 Nov 08;11:9495-9503
pubmed: 31807075
J Clin Oncol. 2019 May 20;37(15):1277-1284
pubmed: 30892988
Expert Rev Hematol. 2015 Apr;8(2):225-35
pubmed: 25719455
Cancer Cell. 2018 Oct 8;34(4):674-689.e8
pubmed: 30245083
Cancers (Basel). 2020 Jun 04;12(6):
pubmed: 32512867
Stem Cells. 2001;19(1):1-11
pubmed: 11209086
Mol Cell Proteomics. 2014 Jun;13(6):1611-24
pubmed: 24722731
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Exp Hematol Oncol. 2020 Mar 16;9:3
pubmed: 32190414
J Proteomics. 2016 Aug 11;145:214-225
pubmed: 27107777
J Oncol. 2019 Jul 30;2019:7239206
pubmed: 31467542
Pharmacol Res. 2020 May;155:104725
pubmed: 32109580
Mol Cell Proteomics. 2019 Jul;18(7):1454-1467
pubmed: 30975897
Expert Rev Hematol. 2018 Oct;11(10):805-816
pubmed: 30092693
Haematologica. 2015 Mar;100(3):331-5
pubmed: 25527568
Mol Cell Proteomics. 2008 Apr;7(4):661-71
pubmed: 18039691
Best Pract Res Clin Haematol. 2019 Dec;32(4):101094
pubmed: 31779986
Leukemia. 2020 Mar;34(3):671-681
pubmed: 31915366
Br J Haematol. 1999 Oct;107(1):69-79
pubmed: 10520026
Am J Hematol. 2013 Apr;88(4):318-27
pubmed: 23526416
J Proteomics. 2018 Feb 20;173:32-41
pubmed: 29175091
Leukemia. 2014 Mar;28(3):716-9
pubmed: 24247654
Cells. 2019 Aug 24;8(9):
pubmed: 31450562
J Proteome Res. 2016 Mar 4;15(3):1023-32
pubmed: 26860878
Int J Mol Sci. 2019 Apr 23;20(8):
pubmed: 31018543
Nat Methods. 2016 Aug 30;13(9):741-8
pubmed: 27575624
J Proteome Res. 2011 Jul 1;10(7):3040-9
pubmed: 21526778
Ann Hematol. 2018 Oct;97(10):1785-1795
pubmed: 29926156
Methods Mol Biol. 2018;1711:133-148
pubmed: 29344888
Leukemia. 2019 May;33(5):1102-1112
pubmed: 30542144
Haematologica. 2011 Sep;96(9):1310-7
pubmed: 21606167
Expert Rev Proteomics. 2017 May;14(5):419-429
pubmed: 28436239
Proteomics. 2005 Aug;5(13):3226-45
pubmed: 16104056
Curr Pharm Biotechnol. 2016;17(1):52-70
pubmed: 26306748
Leukemia. 2015 Jan;29(1):51-7
pubmed: 24913728
Biol Proced Online. 2016 Jun 21;18:13
pubmed: 27330413
Blood. 2019 Feb 14;133(7):676-687
pubmed: 30510081
J Pathol. 2018 Apr;244(5):628-637
pubmed: 29344964
Proteomes. 2018 Dec 20;7(1):
pubmed: 30577422
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Br J Haematol. 2007 Feb;136(4):624-7
pubmed: 17223919
Nat Methods. 2019 Sep;16(9):809-812
pubmed: 31406385
Blood. 2014 Sep 4;124(10):1645-54
pubmed: 25006128
Am J Hematol. 2014 Nov;89(11):1063-81
pubmed: 25318680
Am J Pathol. 2017 Oct;187(10):2175-2184
pubmed: 28736317
N Engl J Med. 1994 Oct 6;331(14):896-903
pubmed: 8078551
Leuk Res. 2018 Oct;73:58-66
pubmed: 30223250
Mol Cell Proteomics. 2014 Nov;13(11):3152-63
pubmed: 25038066
J Sep Sci. 2012 Dec;35(23):3293-301
pubmed: 23109362
Mol Cell Proteomics. 2017 Feb;16(2):300-309
pubmed: 27890865
Proteomics Clin Appl. 2015 Apr;9(3-4):423-31
pubmed: 25504492
J Proteome Res. 2017 Feb 3;16(2):728-737
pubmed: 28107008
Clin Epigenetics. 2013 Jul 30;5(1):12
pubmed: 23898968
Mol Cell Proteomics. 2002 May;1(5):376-86
pubmed: 12118079
Oncol Ther. 2019 Jun;7(1):33-65
pubmed: 32700196
Blood Lymphat Cancer. 2019 Jun 27;9:19-32
pubmed: 31413655
Proteomes. 2018 Feb 12;6(1):
pubmed: 29439554
Nat Protoc. 2018 Jul;13(7):1632-1661
pubmed: 29988108
Methods Mol Biol. 2016;1355:123-33
pubmed: 26584922
Cancers (Basel). 2019 Jan 10;11(1):
pubmed: 30634713
Mol Cell Proteomics. 2014 Sep;13(9):2513-26
pubmed: 24942700
Expert Opin Drug Discov. 2017 Oct;12(10):1053-1065
pubmed: 28748730
Nat Protoc. 2009;4(5):698-705
pubmed: 19373234
Lancet. 2013 Feb 9;381(9865):484-95
pubmed: 23399072
CA Cancer J Clin. 2019 Jul;69(4):305-343
pubmed: 31116423
Cell. 2018 Sep 20;175(1):159-170.e16
pubmed: 30241606
Cancers (Basel). 2018 Sep 14;10(9):
pubmed: 30223538
Proteomics. 2005 Aug;5(13):3262-77
pubmed: 16052621
Biol Blood Marrow Transplant. 2017 Apr;23(4):654-658
pubmed: 28189904
Nat Methods. 2013 Nov;10(11):1046-7
pubmed: 24037243
Mol Cell Proteomics. 2020 Apr;19(4):716-729
pubmed: 32051234
N Engl J Med. 2018 Jun 21;378(25):2386-2398
pubmed: 29860938
Cancers (Basel). 2020 Jul 19;12(7):
pubmed: 32707721
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Cell Syst. 2016 Mar 23;2(3):185-95
pubmed: 27135364
Blood. 2007 Dec 15;110(13):4606-13
pubmed: 17873123
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):37-44
pubmed: 29222235
Anal Chem. 2003 Apr 15;75(8):1895-904
pubmed: 12713048
J Clin Med. 2019 Jul 04;8(7):
pubmed: 31277464
J Pathol. 2020 May;251(1):100-112
pubmed: 32154592
Best Pract Res Clin Haematol. 2014 Sep-Dec;27(3-4):235-40
pubmed: 25455272
Expert Rev Proteomics. 2017 Aug;14(8):649-663
pubmed: 28693350
Cancer. 2012 Dec 15;118(24):6110-7
pubmed: 22736495
Biol Blood Marrow Transplant. 2019 May;25(5):1045-1052
pubmed: 30500442
Am J Hematol. 2015 Mar;90(3):208-14
pubmed: 25421221
EMBO Mol Med. 2019 Nov 7;11(11):e10427
pubmed: 31566909
Front Genet. 2019 Mar 01;10:133
pubmed: 30881380
PLoS One. 2014 Sep 22;9(9):e107587
pubmed: 25244440
Blood. 2018 Mar 22;131(12):1275-1291
pubmed: 29330221